A Phase 2/3 interventional study of LCZ696 and Enalapril in Pediatric Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 98 sites in 29 countries. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2023-02-10.
Sponsored by Novartis Pharmaceuticals · Phase 2/3, Interventional, and Treatment
This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes, metabolizes and removes the drug LCZ696. This will help determine the proper dose of LCZ696 for Part 2 of the study.
The purpose for Part 2 is to compare the effectiveness and safety of LCZ696 with enalapril in a double-blind manner, in pediatric heart failure patients over 52 weeks of treatment.
This study consists of two parts (Part 1 and Part 2). The purpose of Part 1 is to evaluate the way the body absorbs, distributes, metabolizes and removes the drug LCZ696. This will help determine the proper dose of LCZ696 for Part 2 of the study.
The purpose for Part 2 is to compare the effectiveness and safety of LCZ696 with enalapril in a double-blind manner, in pediatric heart failure patients over 52 weeks of treatment.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's enrollment of 393 is above the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
LCZ696 open label: For Age Groups 1 and 2, either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. For Age Group 3, either 1) 0.4 mg/kg or 2) 1.6 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril provided locally by the study site, or standard of care also provided locally by the study site, for heart failure treatment, if patient intended to participate in Part 2.
Drug: LCZ696 · Drug: Enalapril
The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose). Administered in a double-blind fashion.
Drug: Enalapril · Drug: Placebo of LCZ696
LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight. Administered in a double-blind fashion.
Drug: LCZ696 · Drug: Placebo of Enalapril
LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Maximum Drug Concentration in Plasma (Cmax)
The analyses of Cmax was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s).
Time frame: Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2
Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Time to Maximum Plasma Concentration (Tmax)
The analyses of Tmax was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s).
Time frame: Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2
Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf)
The analyses of AUCinf was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s).
Time frame: Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2
Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Number of Participants With Area Under the Plasma Concentration-time Curve From Time Zero to Last (AUClast)
As prespecified in protocol and SAP the analysis of this outcome measure was done based on dose of LCZ696 administered within the different age groups.
Time frame: Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2
Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, and Valsartan): Clearance From Plasma (CL/F)
The analyses was based on plasma concentrations of two sacubitril/valsartan analytes (AHU377 (sacubitril), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s). CL/F was not estimated for LBQ657 as it is a metabolite.
Time frame: Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2
Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril): Time Required to Drug Concentration to Decrease by Half (T 1/2)
The analyses of T1/2 was based on plasma concentrations of sacubitril. The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s). T1/2 for other analytes of LCZ696 (LBQ657 and Valsartan) was not estimable due to the short sample collection timeframe.
Time frame: Age group 1: Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3: Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2
Part 1: Pharmacodynamics (PD) of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma B-type Natriuretic Peptide (BNP)
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included plasma BNP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
Time frame: Baseline (0 hrs pre dose), 4 and 8 hrs post dose on Day 1 of Period 1 and Period 2
Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma N-terminal Pro-brain Natriuretic Peptide (NTproBNP)
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included plasma NTproBNP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
Time frame: Baseline (0 hrs pre dose) and optional 24 hrs post dosing on Day 1 of Period 1 and Period 2
Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Plasma Cyclic Guanosine Monophosphate (cGMP)
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included plasma cGMP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
Time frame: Baseline (0 hrs pre dose), 4 and 8 hrs post dose on Day 1 of Period 1 and Period 2
Part 1: Pharmacodynamics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Change From Baseline in Urine cGMP
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included urine cGMP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
Time frame: Baseline (0 hrs pre dose), 4 to 8 hrs post dose on Day 1 of Period 1 and Period 2
Part 2: Percentage of Participants With Worst Event in Each Category Based on Global Ranking
Global ranking is based on 5 categories ranking worst to best outcome:Category 1:Death; United Network for Organ Sharing(UNOS)status 1A listing for heart transplant or equivalent; ventricular assist device(VAD)/extracorporeal membrane oxygenation(ECMO)/mechanical ventilation/intra-aortic balloon pump requirement for life support at end of study. Category 2:Worsening HF(WHF);defined by signs and symptoms of WHF that requires an intensification of HF therapy. Category 3:Worsened; worse New York Heart Association(NYHA)/Ross or worse Patient Global Impression of Severity(PGIS); and further ranking by Pediatric Quality of Life Inventory(PedsQL)physical functioning domain.Category 4:Unchanged; unchanged NYHA/Ross and unchanged PGIS; and further ranking by PedsQL physical functioning domain. Category 5:Improved; improved NYHA/Ross or improved PGIS(neither can be worse);and further ranking by PedsQL physical functioning domain. Participants with worst event in each category are reported here.
Time frame: Up to 52 weeks
Part 1: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence associated with use of a drug in humans, whether considered drug related or not, that occurs after a participant provides informed consent. TEAEs during part 1 are defined as any recorded AE with its start date (recorded or imputed) later than or equal to the date of the first dose of the study drug within part 1 and its start date prior to or equal to the end date of the part 1.
Time frame: From first dose to 30 days after last dose of study drug in Part 1
Part 2: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. TEAEs during part 2 are defined as any recorded AE with its start date (recorded or imputed) later than or equal to the date of the first dose of the study drug within part 2 and its start date prior to or equal to the end date of part 2.
Time frame: From first dose to 30 days after last dose of study drug in Part 2 (up to 56 weeks)
Part 2: Exposure-adjusted Incidence Rate of Category 1 or Category 2 Event
The exposure adjusted incidence rate is calculated as number of participants with at least one event divided by total participant years across all participants. Category 1: Death; UNOS status 1A listing for heart transplant or equivalent; VAD/ECMO/mechanical ventilation/intra-aortic balloon pump requirement for life support at end of study. Category 2: WHF; defined by signs and symptoms of WHF that requires an intensification of HF therapy.
Time frame: 52 weeks
Part 2: Percentage of Participants With Change From Baseline in New York Heart Association (NYHA)/Ross Functional Class
NYHA classification is a subjective physician's assessment of participant's functional capacity and symptomatic status and can change frequently over time. NYHA is tool that classifies participants with heart failure into one of four classes according to their degree of symptoms at rest and with activity. Class I: No limitations of physical activity. Class 2: May experience fatigue, palpitations, dyspnea, or angina during moderate exercise but not during rest. Class 3: Symptoms with minimal exertion that interfere with normal daily activity. Class 4: Unable to carry out any physical activity because they typically have symptoms of HF at rest that worsen with any exertion. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
Time frame: Baseline, Week 4, 12, 24, 36, and 52
Part 2: Percentage of Participants With Change From Baseline in Patient Global Impression of Severity (PGIS) Score
PGIS of Heart Failure Symptoms is a 1-item questionnaire to assess the participant's impression of symptoms severity, specifically: shortness of breath, fatigue and swelling. The PGI-S asks the participant to choose one response that best describes how his/her heart failure symptoms, specifically: shortness of breath, fatigue and swelling are now on a 5-point scale, ranging from 'Not at all' (1) to 'Very severe' (5). C1 = none (good), C2 = mild, C3 = moderate, C4 = severe, C5 = very severe (bad). Percentage of participants by change in score are reported. Participants with change from baseline were classified as improved (shifted from higher to score), unchanged (no change in score) or worsened (shifted from lower to higher score).
Time frame: Baseline, Week 4, 12, 24, 36, and 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Clearance From Plasma (CL)
The analyses of CL was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Volume of Distribution in Steady State
The analyses of volume of distribution was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Absorption Rate Constant (Ka)
The analyses of Ka was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Time Required to Drug Concentration to Decrease by Half (T 1/2)
The analyses of T1/2 was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Maximum Drug Concentration in Plasma at Steady State (Cmax,ss)
The analyses of Cmax was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin,ss)
The analyses of Cmin was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
Part 1 and Part 2: Population PK of LCZ696 Analytes: Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval Tau at Steady State (AUCtau,ss)
The analyses of AUCtau was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
Time frame: Part 1: Age group 1- Pre-dose and 0.5, 1, 2, 4, 8, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Age groups 2 and 3- Pre-dose and 1, 2, 4, 10, optional 24 hours post-dose on Day 1 of Period 1 and 2; Part 2: Weeks 2, 8, 12, 52
2-Part (Pt) Study: Pt 1 a single dose PK/PD study with 2 dose levels; Pt 2 is a 52-week, double blind, active controlled, randomized, safety \& efficacy study. In Pt 1, there were 3 age groups: 6 to \<18 yrs, 1 to \<6 yrs and 1 month to \<1 yr. Each received either a single low dose LCZ696 (Cohort 1), a single high dose LCZ696 (Cohort 2) or both. Cohort S included patients receiving a single low dose after having received a single high dose. The low/high doses for groups 1/2 were 0.8 \& 3.1 (mg/kg).
| Milestone | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|---|---|---|
| Started | 17 | 0 | 0 | 0 | 0 |
| Completed | 14 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|---|---|---|
| Started | 0 | 18 | 2 | 0 | 0 |
| Completed | 0 | 18 | 2 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 187 | 188 |
| Completed | 0 | 0 | 0 | 169 | 164 |
| Not completed | 0 | 0 | 0 | 18 | 24 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 8 | 12 |
| Withdrew: Technical problems | 0 | 0 | 0 | 4 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Subject/guardian decision | 0 | 0 | 0 | 5 | 6 |
The analyses of Cmax was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s).
| nanograms per milliliter (ng/ml) | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Sacubitril | 523 ± 390 | 179 ± 97 | 1970 ± 1666 | 549 ± 298 | 124 ± 80 | 433 ± 181 |
| LBQ657 | 1951 ± 839 | 1359 ± 711 | 6707 ± 1887 | 5453 ± 1032 | 632 ± 89 | 2326 ± 629 |
| Valsartan | 1271 ± 1011 | 1112 ± 583 | 4035 ± 1678 | 4935 ± 1268 | 440 ± 275 | 2487 ± 1564 |
The analyses of Tmax was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s).
| hours (hr) | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Sacubitril | 1.1 ± 1.3 | 1.2 ± 0.5 | 0.8 ± 0.3 | 1.2 ± 0.4 | 1.1 ± 0.1 | 1.0 ± 0.0 |
| LBQ657 | 4.0 ± 2.0 | 2.9 ± 1.1 | 2.9 ± 1.1 | 3.6 ± 3.2 | 2.8 ± 1.6 | 3.6 ± 0.9 |
| Valsartan | 1.7 ± 1.1 | 2.1 ± 1.4 | 2.6 ± 1.0 | 1.9 ± 0.4 | 1.8 ± 1.5 | 1.8 ± 1.3 |
The analyses of AUCinf was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s).
| hr*ng/mL | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Sacubitril | 690 ± 410 | 494 ± 286 | 3021 ± 1814 | 1214 ± 684 | 270 ± 182 | 1063 ± 266 |
| LBQ657 | 48264 ± 22939 | 31042 ± 17259 | 150440 ± 49515 | 127625 ± 35634 | 15835 ± 2912 | 62377 ± 16035 |
| Valsartan | 13540 ± 12962 | 11036 ± 7031 | 40733 ± 21003 | 48561 ± 21163 | 3923 ± 1424 | 26170 ± 16826 |
As prespecified in protocol and SAP the analysis of this outcome measure was done based on dose of LCZ696 administered within the different age groups.
| Participants | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril, LBQ657, and Valsartan): Number of Participants With Area Under the Plasma Concentration-time Curve From Time Zero to Last (AUClast) | 7 | 8 | 7 | 6 | 4 | 5 |
The analyses was based on plasma concentrations of two sacubitril/valsartan analytes (AHU377 (sacubitril), and valsartan). The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s). CL/F was not estimated for LBQ657 as it is a metabolite.
| liter per hour per kilograms (L/hr/kg) | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Sacubitril | 0.73 ± 0.35 | 1.19 ± 0.96 | 0.63 ± 0.28 | 1.67 ± 1.01 | 1.19 ± 1.11 | 1.67 ± 1.01 |
| Valsartan | 0.06 ± 0.05 | 0.07 ± 0.09 | 0.06 ± 0.06 | 0.04 ± 0.01 | 0.06 ± 0.02 | 0.05 ± 0.03 |
The analyses of T1/2 was based on plasma concentrations of sacubitril. The plasma levels of sacubitril/valsartan analytes were determined using a validated LCMS/MS method with a lower limit of quantitation (LLOQ) of 1 ng/mL for sacubitril, 20 ng/mL for LBQ657, and 10 ng/mL for valsartan. The PK parameters were determined using the non-compartmental method(s). T1/2 for other analytes of LCZ696 (LBQ657 and Valsartan) was not estimable due to the short sample collection timeframe.
| hours | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Part 1: Pharmacokinetics of LCZ696 Analytes (Sacubitril): Time Required to Drug Concentration to Decrease by Half (T 1/2) | 1.26 (0.95 to 2.36) | 1.53 (1.40 to 1.65) | 1.34 (1.16 to 1.60) | 1.51 (1.34 to 1.70) | — | 1.33 (1.16 to 1.64) |
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included plasma BNP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
| picomoles per liter (pmol/L) | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Baseline (0 hrs pre dose) | 100.87 (49.84 to 204.13) | 63.80 (8.65 to 470.81) | 97.52 (51.59 to 184.32) | 120.51 (5.21 to 2787.44) | 21.20 (2.14 to 210.41) | 129.29 (9.45 to 1768.43) |
| Change From Baseline (4 hrs post dose) | 1.31 (0.93 to 1.85) | 1.60 (0.21 to 11.95) | 1.22 (0.94 to 1.58) | 0.62 (NA to NA) | 0.77 (0.56 to 1.05) | 1.09 (0.61 to 1.93) |
| Change From Baseline (8 hrs post dose) | 1.32 (0.92 to 1.88) | 1.21 (0.21 to 7.04) | 0.97 (0.70 to 1.34) | 0.80 (NA to NA) | 0.59 (0.27 to 1.30) | 0.55 (0.15 to 2.02) |
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included plasma NTproBNP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
| picograms per millilitre (pg/mL) | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Baseline (0 hrs pre dose) | 2385.34 (1186.13 to 4796.98) | — | 2179.94 (932.77 to 5094.69) | — | 961.76 (125.65 to 7361.70) | 5086.37 (683.53 to 37849.47) |
| Change From Baseline (24 hrs post dose) | 0.74 (0.31 to 1.78) | — | — | — | 0.59 (0.00 to 134.25) | 0.41 (0.34 to 0.48) |
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included plasma cGMP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
| nanomoles per litre (nmol/L) | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Baseline (0 hrs pre dose) | 18.18 (12.01 to 27.51) | 21.41 (12.83 to 35.71) | 12.20 (8.13 to 18.32) | 24.55 (18.37 to 32.82) | 13.38 (0.05 to 3883.59) | 22.84 (12.51 to 41.68) |
| Change From Baseline (4 hrs post dose) | 1.30 (0.89 to 1.90) | 0.90 (0.50 to 1.62) | 1.54 (1.12 to 2.10) | 1.02 (0.52 to 2.01) | 0.80 (0.00 to 618.02) | 0.78 (0.27 to 2.22) |
| Change From Baseline (8 hrs post dose) | 1.17 (0.91 to 1.50) | 0.92 (0.66 to 1.29) | 1.60 (1.10 to 2.31) | 0.40 (0.02 to 8.86) | 0.79 (0.00 to 230.10) | 0.79 (0.29 to 2.18) |
Biomarkers were used to assess the PD effects of LCZ696. Blood biomarkers of potential interest included urine cGMP. Biomarkers related to heart failure or the mechanism of action of the study drug were measured. Summary statistics for change from baseline at each time point is presented. The baseline assessment is defined as the last non-missing assessment (scheduled or unscheduled) prior to (the first dose time of the study drug within the dose associated period). For each post-dose time point, participants are included if and only if the participant has both pre-dose assessment and current time point assessment observed.
| nmol/L | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) |
|---|---|---|---|---|---|---|
| Baseline (0 hrs pre dose) | 1055.56 (352.98 to 3156.55) | 1349.91 (118.48 to 15380.33) | 914.57 (311.65 to 2683.88) | 1123.69 (75.21 to 16789.03) | 485.00 (NA to NA) | 386.32 (134.04 to 1113.42) |
| Change From Baseline (4 to 8 hrs post dose) | 1.42 (0.38 to 5.32) | 0.80 (0.02 to 27.03) | 1.79 (0.65 to 4.96) | 2.17 (0.10 to 45.16) | 0.92 (0.02 to 51.75) | 1.98 (0.51 to 7.63) |
Global ranking is based on 5 categories ranking worst to best outcome:Category 1:Death; United Network for Organ Sharing(UNOS)status 1A listing for heart transplant or equivalent; ventricular assist device(VAD)/extracorporeal membrane oxygenation(ECMO)/mechanical ventilation/intra-aortic balloon pump requirement for life support at end of study. Category 2:Worsening HF(WHF);defined by signs and symptoms of WHF that requires an intensification of HF therapy. Category 3:Worsened; worse New York Heart Association(NYHA)/Ross or worse Patient Global Impression of Severity(PGIS); and further ranking by Pediatric Quality of Life Inventory(PedsQL)physical functioning domain.Category 4:Unchanged; unchanged NYHA/Ross and unchanged PGIS; and further ranking by PedsQL physical functioning domain. Category 5:Improved; improved NYHA/Ross or improved PGIS(neither can be worse);and further ranking by PedsQL physical functioning domain. Participants with worst event in each category are reported here.
| percentage of participants | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|
| Category 1 | 10.16 | 15.96 |
| Category 2 | 9.63 | 4.79 |
| Category 3 | 6.95 | 5.85 |
| Category 4 | 20.86 | 26.60 |
| Category 5 | 39.57 | 35.64 |
| Missing | 12.83 | 11.17 |
An adverse event (AE) is any untoward medical occurrence associated with use of a drug in humans, whether considered drug related or not, that occurs after a participant provides informed consent. TEAEs during part 1 are defined as any recorded AE with its start date (recorded or imputed) later than or equal to the date of the first dose of the study drug within part 1 and its start date prior to or equal to the end date of the part 1.
| percentage of participants | LCZ696: 0.8 mg/kg (Age Group 1) | LCZ696: 0.8 mg/kg (Age Group 2) | LCZ696: 3.1 mg/kg (Age Group 1) | LCZ696: 3.1 mg/kg (Age Group 2) | LCZ696: 0.4 mg/kg (Age Group 3) | LCZ696: 1.6 mg/kg (Age Group 3) | Part 1: Dose Cohort S |
|---|---|---|---|---|---|---|---|
| Part 1: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | 28.57 | 50.00 | 28.57 | 50.00 | 50.00 | 80.00 | 50.00 |
An AE is any untoward medical occurrence associated with use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent. TEAEs during part 2 are defined as any recorded AE with its start date (recorded or imputed) later than or equal to the date of the first dose of the study drug within part 2 and its start date prior to or equal to the end date of part 2.
| percentage of participant | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|
| Part 2: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) | 88.77 | 87.77 |
The exposure adjusted incidence rate is calculated as number of participants with at least one event divided by total participant years across all participants. Category 1: Death; UNOS status 1A listing for heart transplant or equivalent; VAD/ECMO/mechanical ventilation/intra-aortic balloon pump requirement for life support at end of study. Category 2: WHF; defined by signs and symptoms of WHF that requires an intensification of HF therapy.
| participant per participant years | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|
| Part 2: Exposure-adjusted Incidence Rate of Category 1 or Category 2 Event | 20.133 (13.9430 to 28.1344) | 20.042 (13.7960 to 28.1464) |
NYHA classification is a subjective physician's assessment of participant's functional capacity and symptomatic status and can change frequently over time. NYHA is tool that classifies participants with heart failure into one of four classes according to their degree of symptoms at rest and with activity. Class I: No limitations of physical activity. Class 2: May experience fatigue, palpitations, dyspnea, or angina during moderate exercise but not during rest. Class 3: Symptoms with minimal exertion that interfere with normal daily activity. Class 4: Unable to carry out any physical activity because they typically have symptoms of HF at rest that worsen with any exertion. Participants with change from baseline were classified as improved (shifted from higher to lower class), unchanged (no change in class) or worsened (shifted from lower to higher class).
| percentage of participants | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|
| Change from Baseline at Week 4: Improved | 14.21 | 15.67 |
| Change from Baseline at Week 4: Unchanged | 84.15 | 82.61 |
| Change from Baseline at Week 4: Worsened | 1.64 | 1.63 |
| Change from Baseline at Week 12: Improved | 23.89 | 25.56 |
| Change from Baseline at Week 12: Unchanged | 70.56 | 67.78 |
| Change from Baseline at Week 12: Worsened | 5.56 | 6.67 |
| Change from Baseline at Week 24: Improved | 26.97 | 27.91 |
| Change from Baseline at Week 24: Unchanged | 64.04 | 63.95 |
| Change from Baseline at Week 24: Worsened | 8.99 | 8.14 |
| Change from Baseline at Week 36: Improved | 29.94 | 34.12 |
| Change from Baseline at Week 36: Unchanged | 61.08 | 58.24 |
| Change from Baseline at Week 36: Worsened | 8.98 | 7.65 |
| Change from Baseline at Week 52: Improved | 37.66 | 33.96 |
| Change from Baseline at Week 52: Unchanged | 50.65 | 56.60 |
| Change from Baseline at Week 52: Worsened | 11.69 | 9.43 |
PGIS of Heart Failure Symptoms is a 1-item questionnaire to assess the participant's impression of symptoms severity, specifically: shortness of breath, fatigue and swelling. The PGI-S asks the participant to choose one response that best describes how his/her heart failure symptoms, specifically: shortness of breath, fatigue and swelling are now on a 5-point scale, ranging from 'Not at all' (1) to 'Very severe' (5). C1 = none (good), C2 = mild, C3 = moderate, C4 = severe, C5 = very severe (bad). Percentage of participants by change in score are reported. Participants with change from baseline were classified as improved (shifted from higher to score), unchanged (no change in score) or worsened (shifted from lower to higher score).
| percentage of participants | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|
| Change from Baseline at Week 4: Improved | 27.01 | 29.67 |
| Change from Baseline at Week 4: Unchanged | 58.05 | 59.89 |
| Change from Baseline at Week 4: Worsened | 14.94 | 10.44 |
| Change from Baseline at Week 12: Improved | 30.90 | 31.46 |
| Change from Baseline at Week 12: Unchanged | 52.25 | 55.62 |
| Change from Baseline at Week 12: Worsened | 16.85 | 12.92 |
| Change from Baseline at Week 24: Improved | 33.33 | 38.01 |
| Change from Baseline at Week 24: Unchanged | 48.85 | 48.54 |
| Change from Baseline at Week 24: Worsened | 17.82 | 13.45 |
| Change from Baseline at Week 36: Improved | 33.33 | 33.94 |
| Change from Baseline at Week 36: Unchanged | 49.38 | 52.73 |
| Change from Baseline at Week 36: Worsened | 17.28 | 13.33 |
| Change from Baseline at Week 52: Improved | 35.53 | 34.81 |
| Change from Baseline at Week 52: Unchanged | 48.03 | 47.47 |
| Change from Baseline at Week 52: Worsened | 16.45 | 17.72 |
The analyses of CL was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| L/h | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 25.93 ± 19.29 |
| LBQ657 | 0.44 ± 0.31 |
| Valsartan | 1.97 ± 1.69 |
The analyses of volume of distribution was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| L/Kg | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 4.67 ± 5.84 |
| LBQ657 | 0.34 ± 0.12 |
| Valsartan | 0.68 ± 0.29 |
The analyses of Ka was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| 1/hour | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 1.25 ± 0.01 |
| LBQ657 | 1.04 ± 1.34 |
| Valsartan | 1.42 ± 0.92 |
The analyses of T1/2 was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| hours | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 8.51 (1.87 to 199.55) |
| LBQ657 | 18.21 (6.08 to 107.47) |
| Valsartan | 7.96 (2.33 to 81.65) |
The analyses of Cmax was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| ng/mL | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 1348 ± 627 |
| LBQ657 | 10153 ± 3591 |
| Valsartan | 3861 ± 1770 |
The analyses of Cmin was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| ng/mL | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 63 ± 141 |
| LBQ657 | 6442 ± 3474 |
| Valsartan | 1442 ± 1564 |
The analyses of AUCtau was based on plasma concentrations of three sacubitril/valsartan analytes (AHU377 (sacubitril), LBQ657 (sacubitrilat), and valsartan). The PK parameters were determined using the non-compartmental method(s). In case of data limitations for estimating PK parameters using non-compartmental methods, a population PK approach was used to estimate exposure of sacubitril/valsartan analytes. The population PK model was developed to describe incoming data from pediatric patients based on an established model developed for the adult population.
| ng/mL*h | LCZ696 (Part 1 and 2) |
|---|---|
| Sacubitril | 2179 ± 2241 |
| LBQ657 | 98906 ± 41944 |
| Valsartan | 28672 ± 19686 |
Collected over Adverse events were collected from first dose of study treatment plus 30 days post treatment up to approximately one year.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Dose Cohort 1 | 0/17 (0%) | 2/17 (11.8%) | 6/17 (35.3%) |
| Part 1: Dose Cohort 2 | 0/18 (0%) | 1/18 (5.6%) | 10/18 (55.6%) |
| Part 1: Dose Cohort S | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Part 2: LCZ696 | 8/187 (4.3%) | 69/187 (36.9%) | 161/187 (86.1%) |
| Part 2: Enalapril | 12/188 (6.4%) | 62/188 (33%) | 156/188 (83%) |
| Event | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/17 | 0/18 | 0/2 | 24/187 | 23/188 |
| Congestive cardiomyopathyCardiac disorders | 1/17 | 0/18 | 0/2 | 0/187 | 1/188 |
| VomitingGastrointestinal disorders | 1/17 | 0/18 | 0/2 | 5/187 | 4/188 |
| InfluenzaInfections and infestations | 1/17 | 0/18 | 0/2 | 2/187 | 2/188 |
| Viral upper respiratory tract infectionInfections and infestations | 0/17 | 1/18 | 0/2 | 0/187 | 2/188 |
| PneumoniaInfections and infestations | 0/17 | 0/18 | 0/2 | 5/187 | 4/188 |
| Cardiac failure congestiveCardiac disorders | 0/17 | 0/18 | 0/2 | 4/187 | 3/188 |
| PyrexiaGeneral disorders | 0/17 | 0/18 | 0/2 | 4/187 | 0/188 |
| Upper respiratory tract infectionInfections and infestations | 0/17 | 0/18 | 0/2 | 4/187 | 0/188 |
| HypotensionVascular disorders | 0/17 | 0/18 | 0/2 | 4/187 | 0/188 |
| Event | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/17 | 4/18 | 1/2 | 33/187 | 37/188 |
| FatigueGeneral disorders | 0/17 | 1/18 | 1/2 | 19/187 | 14/188 |
| Peripheral swellingGeneral disorders | 0/17 | 1/18 | 1/2 | 0/187 | 2/188 |
| Swelling faceGeneral disorders | 0/17 | 1/18 | 1/2 | 1/187 | 1/188 |
| Upper respiratory tract infectionInfections and infestations | 0/17 | 3/18 | 1/2 | 37/187 | 35/188 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/17 | 1/18 | 1/2 | 36/187 | 38/188 |
| PyrexiaGeneral disorders | 0/17 | 1/18 | 0/2 | 36/187 | 34/188 |
| NasopharyngitisInfections and infestations | 0/17 | 0/18 | 0/2 | 29/187 | 17/188 |
| DiarrhoeaGastrointestinal disorders | 0/17 | 0/18 | 0/2 | 25/187 | 23/188 |
| DizzinessNervous system disorders | 0/17 | 0/18 | 0/2 | 23/187 | 15/188 |
Full Analysis Set included all randomized participants who received study drug, with the exception of \[2 patients in Part 2\] who had not received any study drug, but had been inadvertently randomized into the study (mis-randomized).
| Age, Continuous(years) | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril | Total |
|---|---|---|---|---|---|---|
| Median | 3.00 (0.30 to 16.00) | 2.50 (0.20 to 17.00) | 1.55 (1.10 to 2.00) | 7.00 (0.50 to 17.00) | 8.50 (0.10 to 18.00) | 4.51 (0.10 to 18.00) |
| Sex: Female, Male(Participants) | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 6 | 0 | 98 | 95 | 207 |
| Male | 9 | 12 | 2 | 89 | 93 | 205 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 0 | 25 | 15 | 43 |
| Not Hispanic or Latino | 9 | 10 | 1 | 134 | 125 | 279 |
| Unknown or Not Reported | 6 | 7 | 1 | 28 | 48 | 90 |
| Race (NIH/OMB)(Participants) | Part 1: Dose Cohort 1 | Part 1: Dose Cohort 2 | Part 1: Dose Cohort S | Part 2: LCZ696 | Part 2: Enalapril | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 0 | 3 | 2 | 8 |
| Asian | 3 | 4 | 0 | 57 | 45 | 109 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 1 | 23 | 25 | 56 |
| White | 9 | 7 | 0 | 87 | 93 | 196 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 1 | 17 | 23 | 43 |
Documents are hosted by the registry — open the source record to download them.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel based on scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals